

CPSA – Where Technology and Solutions Meet

1998 Program Chairs

Mike S. Lee, Milestone Development Services
Edward H. Kerns, Milestone Development Services

Plenary Lecture

Richard A. Yost, University of Florida
Pushing the Bioanalytical Envelope with Ion Trap Mass Spectrometry

Featured Symposia and Roundtables

Metabolism || Analysis Strategies || Emerging Technologies || Biomolecular Separations || Automation || Combinatorial Chemistry || Impurities, Degradants and Natural Products || Recruiting, Developing and Motivating Scientists || Outsourcing || Biomolecule Analysis || Pharmacokinetics

1999 Program Chair

Mike S. Lee, Milestone Development Services

Plenary Lecture

Richard M. Caprioli, Vanderbilt University
Mass Spectrometry Imaging: A Tool for the 21st Century

Featured Symposia and Roundtables

Proteomics || Sample Preparation || Combinatorial Chemistry || Automation || Fast Chromatography || Lead Optimization || Accelerated Drug Discovery || Using Dedicated Instruments || Well Characterized Biologics || Information Management || Lead Identification || Emerging Technologies

2000 Program Chair

Todd A. Gillespie, Eli Lilly and Company

Plenary Lecture

John R. Yates, The Scripps Research Institute
Proteomics Using Multidimensional Chromatography and Tandem Mass Spectrometry

Featured Symposia and Roundtables

New Technologies and Approaches for Drug Metabolism || Sample Preparation || Chromatography || Structure and Purity Determination: How Much and When? || How to Demo/Purchase an LC/MS Instrument: Experiences and Perspectives || Drug Discovery in the Post-Genome Era: Proteomics/Genomics || Predictive Models for Lead Optimization and Selection || Mass Spectrometry || Data Management || Mass Spectrometry in the QC Laboratory: Are We Ready? || Purification Systems for Combinatorial Chemistry || Is LC/TOF a Viable Bioanalytical Tool? || Data Management and Manipulation || Drugability High Throughput Screening || In Vitro Methods || New Technologies and Future Trends for High Throughput

2001 Program Chair

Robyn A. Rourick, DuPont Pharmaceuticals

Plenary Lecture

Donald G. Robertson, Pfizer

Of Mice and Magnets: Metabonomic Technology as a Tool for Rapid-Throughput Toxicity Evaluation

Featured Symposia and Roundtables

Structure Profiling || Sample Preparation & Chromatography || High Throughput Synthesis Support: Open-Access Applications and Formats || The Emerging Future/Role of Proteomics in Drug Discovery || Pharmaceutical Property Profiling: Metrics and Implementation || Mass Spectrometry & Data Management || Hyphenated NMR Methods in Pharmaceutical R&D || Strategies for Overcoming the Bottlenecks in Assessing Toxicity || Predictive Models for Drug Discovery Screening || Technology Transfer: Drug Discovery to Drug Development Perspectives || Emerging Technologies

2002 Program Chair

Kenneth L. Morand, Procter & Gamble Pharmaceuticals

Plenary Lecture

Joseph A. DiMasi, Tufts Center for the Study of Drug Development

Trends in the Economics of Pharmaceutical Innovation: Cost, Time, and Risk

Featured Symposia and Roundtables

Genomics/Post-Genomics Trends || Instrumentation for Protein Characterization: Emerging Trends in Proteomic Analysis || Metabonomics || Advances in Microfluidics Technology || The Value of the Corporate Compound Collection: Protecting Your Investment || Preclinical Lead Optimization: Are We Making A Difference? || Emerging Technologies for Drug Discovery & Development || Data Management in a High-Throughput Analysis Environment || Why Does Method Development Take So Long? || In-Source, Out-Source: What Do Pharmaceutical Companies Do for Bioanalytical Support? || Crystal City Guideline Review

2003 Program Chair

Nigel J. Clarke, ActivX Biosciences

Plenary Lecture

Simon J. Gaskell, The University of Manchester Institute of Science and Technology

The Multi-Dimensionality of the Proteome

Featured Symposia and Roundtables

Functional Proteomics: Quantitation || Discovery and Validation of Proteomic Biomarkers for Drug Development || Functional Proteomics: Relationships || Bioinformatics for Proteomics || Lead Optimization || Reactive Xenobiotic Intermediates || Compound Library Analysis and Profiling || Conversion of Data to Information: Dissemination of Information to Drive Therapeutic Area Projects || Recent Regulatory Guidance: Bioanalytical Impact on Drug Development || Bioanalytical LC/MS/MS Methods: Perspectives and Lessons Learned || Research Informatics in Drug Development

2004 Program Chairs

Steven A. Hofstadler, Ibis Therapeutics
Mark Sanders, Bristol-Myers Squibb

Plenary Lecture

Richard D. Smith, Pacific Northwest National Laboratory
Quantitative and Ultra-Sensitive High Throughput Proteomics

Keynote Lectures

David H. Russell, Texas A&M University
Molecular Imaging Using MALDI and Ion Mobility-Mass Spectrometry: A New Paradigm for Proteomics

Richard Beger, Food & Drug Administration
Metabolic Profiles of Drug Toxicity and Disease

Featured Symposia and Roundtables

Biomarkers: Initiatives, Perspectives & Approaches || How Do We Set Priorities in Drug Discovery & Development? || Outsourcing Trends: Emerging Business Models & Overseas Partners || High Throughput Analysis & Information Management Strategies || Current Strategies & Preferences for Metabolite Identification || Biomarker Discovery || High Throughput ADME & Pharmaceutical Property Profiling || Tissue Imaging: Localization of Drugs & Metabolites || Biomarker Evaluation || Emerging Technologies & Applications

2005 Program Chair

Bradley L. Ackermann, Eli Lilly and Company

Plenary Lecture

R. Graham Cooks, Purdue University
Enabling Biology Through Analytical Innovation: Tissue Imaging in the Ambient Environment Using DESI Mass Spectrometry

Keynote Lectures

Yining Zhao, Pfizer
Modern Separation Science: Quo Vadis? – The Pursuit of Higher Resolution and Higher Speed Separation in Drug Discovery and Development

John T. Stults, Predicant Biosciences
Discovery and Clinical Validation of Serum Biomarkers for Disease Diagnosis

Distinguished Analytical Scientist Award

Mark J. Cole, Pfizer

Featured Symposia and Roundtables

Biomarkers: Proteomics Strategies || Metabolite Identification: Emerging Strategies to Make Better Use of Time & Resources || Chromatography || Bioanalytical: Current Strategies || Pharmaceutical Properties: Compound Library Analysis & Profiling || Biomarkers: Metabonomics Strategies || Bioanalytical: Driving Technologies & Methodologies || Pharmaceutical Properties: HT ADME || Biomarkers: New Technologies & Approaches || NMR Analysis: Emerging Analysis Strategies & Methodologies || Bioanalytical: Exploratory Technologies

2006 Program Chair

Jing-Tao Wu, Millennium Pharmaceuticals

Plenary Lecture

Mark L. Powell, Bristol-Myers Squibb

Analytical Chemistry: A Changing Paradigm of Advanced Process Models, Tools and Technologies in R&D

Keynote Lectures

Richard C. King, Merck Research Laboratories

Ion Formation from Complex Solutions: Understanding Matrix Effects and Ionization Suppression

David M. Lubman, University of Michigan

Markers of Cancer Using a Liquid Proteomics Approach

Distinguished Analytical Scientist Award

Richard C. King, Merck Research Laboratories

Featured Symposia and Roundtables

Proteins and Early Biology || Discovery Strategy: The Minimalist Approach Versus the Fail Faster Model || Predictive Toxicology || Measurement of Drug in Clinical Development || Pharmaceutical Sciences - Analytical New Strategies || Chemistry in Drug Discovery || The Unsolved Mystery: Reactive Metabolites || AAPS/FDA Bioanalytical Workshop: Take Home Messages and Implementation || Clinical Development – Measurement of Drug Effects || Biomarkers in Drug Discovery || Pharmaceutical Sciences - Analytical New Technologies || Emerging New Technologies || Pharmacokinetics & Pharmacodynamics

2007 Program Chair

Nalini Sadagopan, Pfizer

Plenary Lecture

Jonathan L. Josephs, Bristol-Myers Squibb

Why Can't We All Just Get Along: An Integrated Approach to Solving ADME Issues

Keynote Lectures

Bradley L. Ackermann, Eli Lilly and Company

From Bioanalytical to Biomarkers - Using Quantitative Mass Spectrometry to Address Biological Bottlenecks

Liang Li, University of Alberta

Development and Applications of Improved Sample Handling and LC-MS Techniques for Comprehensive Proteome and Metabolome Analysis

Distinguished Analytical Scientist Award

Bradley L. Ackermann, Eli Lilly and Company

Featured Symposia and Roundtables

Biomarkers in Preclinical Development || Bioanalytical CRO – Assay Transfers || Proteo-Metabonomic Strategies in Drug Development || High Throughput Approaches – Fast Separations || Biologics || Metabolomics and Metabonomics || Omics Technologies || New Technologies and Trends in Bioanalysis || Drug Metabolism in Preclinical and Clinical Development || Driving Pharmaceutical Quality || Biomarkers in Clinical Development || ADME Strategies: Past, Present and Future

2008 Program Chair

Lucinda Cohen, Merck Research Laboratories

Plenary Lecture

David M. Hercules, Vanderbilt University

Mass Spectrometry of Synthetic Polymers: Some Challenges and Some Successes

Keynote Lectures

Thomas R. Covey, MDS Analytical Technologies

Where Can We Go From Here? An Assessment of the Limits to Sensitivity of Electrospray and MALDI

J. Michael Ramsey, University of North Carolina

Protein and Peptide Analysis Using Microfabricated Fluidic Devices

Distinguished Analytical Scientist Award

Thomas R. Covey, MDS Analytical Technologies

Featured Symposia and Roundtables

Excellence in Bioanalysis Through Automation || Insourcing, Outsourcing and Offshoring || Emerging Analytical Tools for Biologics || "Nano" Applications to Small Molecule Analysis || Biomarkers in Preclinical and Clinical Development || Adding Another Dimension to the Quantitation of Peptides and Proteins || Leveraging Analytical Chemistry for Drug Metabolism Studies || Operational Excellence through IT and Hardware Solutions || Approaches to Overcome Poor Pharmacokinetic Properties for Lead Compounds || Is There Life Beyond LC/MS?

2009 Program Chair

Kevin P. Bateman, Merck Frosst Canada

Plenary Lecture

Ian Jardine, Thermo Fisher Scientific

The Impact of High-Performance Mass Spectrometry on Biology Research

Keynote Lectures

Walter A. Korfmacher, Schering-Plough Research Institute

Using Mass Spectrometry in Drug Discovery: Past, Present and Future

Thomas A. Baillie, University of Washington

The Impact of Mass Spectrometry in Pharmaceutical Lead Optimization – Studies on Metabolic Activation

Distinguished Analytical Scientist Award

Walter A. Korfmacher, Schering-Plough Research Institute

Featured Symposia and Roundtables

High Performance Workflows: Emerging Applications for Simultaneous Qualitative-Quantitative Analysis || Why Biomarkers for Toxicology and Clinical Diagnostics Fail or Don't Have Broader Acceptance? || Small Interfering RNA and Gene Silencing: Emerging Opportunities for Analysis in Drug Discovery and the Potential of a Bioanalytical Equivalent || Small Molecule Biomarker Assay Development and Validation || Protein Based Biomarkers || Tools for Understanding Biology Through Analysis || Toxicity Markers || Peptide and Protein Quantitation: Are Trypsin and MRM Sufficient? || High Throughput Quantitation: Going Faster by Going Faster and Going Slower || Maintaining Our Innovative Fitness During Times of Transition

2010 Program Chair

Petia Shipkova, Bristol-Myers Squibb

Plenary Lecture

Bradley L. Ackermann, Eli Lilly and Company

Using Quantitative Mass Spectrometry to Enable Clinical Translation Through Analysis of Biochemical Markers

Keynote Lectures

Jonathan Josephs, Bristol-Myers Squibb

Accuracy for the Masses: Resolution of the Quan/Qual Debate

Mark Sanders, Thermo Fisher Scientific

Resolution for the Masses: The Debate is Over – Now What?

Distinguished Analytical Scientist Award

Mark Sanders, Thermo Fisher Scientific

Featured Symposia and Roundtables

Biomarker/Toxicity Marker Discovery || A Practical Guide to Regulated Bioanalysis || High-Resolution Technologies and Applications || DMPK with Accurate Mass Measurements || Can Dried Blood Spots Revolutionize Our Industry? Case Studies and Practical Considerations || Biologics as Pharmaceutical Agents || Imaging and Tissue Analysis || International Harmonization of Bioanalytical Guidance || Recent Trends in ADME || Protein/Peptide Biomarkers || Bioinformatics || Where Do We Go From Here?